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Abstract
Background: The recently suggested distinct pathogenic pathways for myeloperoxidase (MPO) and proteinase 3 (PR3)
anti-neutrophilic cytoplasmic antibodies (ANCA) associated vasculitis could result in different modes of presentation
and outcome. Moreover, kidney outcome was related to a new histopathologic classification of pauci-immune
glomerulonephritis. As reports were not always concordant, possible because differences in severity of organ
lesions and ethnicity, we evaluated the outcome of a cohort of Central-East European patients with crescentic
glomerulonephritis in relation with ANCA specificity and histopathological classification.
Methods: Seventy-five patients were consecutively diagnosed by kidney biopsy (76 % MPO-ANCA specificity,
52 % crescentic) and followed for a median period of 3.2 years. Study end-points were response to therapy, end
stage renal disease (ESRD) and death.
Results: PR3-ANCA patients were younger, in higher proportion male and had higher Birmingham Vasculitis
Activity Scores (BVAS). The kidney disease was severe at presentation (median creatinine 5 mg/dL; 27 % required
temporary dialysis) and worst in PR3-ANCA positive patients (50 % patients needed temporary dialysis vs. 19 %). The
lung was the second most affected organ (31 % severe lung hemorrhage). Lung and kidney damage were related; the
odds of hemorrhagic alveolitis in patients needing dialysis at presentation were 4 (95 % CI 1–13; p = 0.006) times higher
than in those who did not. The rate of response to therapy (without signs of active vasculitis and stable or declining
serum creatinine) was 60 % and was associated with dialysis independency, older age and higher platelet number at
presentation. The probabilities to survival 1 and 5 years for kidney and patient were 93 and 64 %, and respectively 88
and 67 %. Kidney survival was predicted by response to therapy and dialysis independency at presentation. Patients
with BVAS < 15 and responding to induction therapy had better chances of survival. Neither response to therapy nor
outcome was influenced by ANCA specificity or by the histopathological class.
Conclusions: When kidney damage is severe in ANCA vasculitis, the need of dialysis at presentation and the response
to induction therapy overcome the prognostic utility of both ANCA specificity and histopathological class.
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Background
ANCA-associated vasculitis is a rare, but severe auto-
immune disease [1–3]. Kidney involvement (i.e. pauci-
immune, crescentic glomerulonephritis), is frequent in
ANCA vasculitis [4, 5] and can cause acute renal injury,
which is potentially fatal, mostly when associated with
pulmonary hemorrhage [6, 7]. Accordingly, patients seen
in a nephrology setting may have distinct clinical fea-
tures from those seen by rheumatologists or pneumolo-
gists and they raise complex therapeutic problems. The
relatively few reported series which addressed patients
with severe kidney disease suggested a poorer outcome
in this set of patients [1, 2, 8, 9]. Whether ANCA type is
related to the severity of vasculitis in patients seen by
nephrologists is a matter of debate [1, 2, 4]. Recent data
suggest distinct pathogenic pathways for myeloperoxi-
dase (MPO) and proteinase 3 (PR3) ANCA vasculitis,
which could result in different modes of presentation
and outcome, although overlapping features are not in-
frequent [10]. However, reports from different groups
are not always concordant, possibly because of differ-
ences in ethnicity (PR3-ANCA is rare in Asians and in
African Americans, where MPO-ANCA is frequent) and
in geographical distribution (in Europe there is a North
to South gradient of incidence in PR3 and a South to
North gradient in MPO) [11–14]. Thus, the potential
differences in phenotype between MPO and PR3-ANCA
are still to be defined [10].
The histological features of kidney biopsy could have a
certain relationship to the outcome. Older studies have
suggested that the proportion of normal glomeruli was a
predictor of a good renal outcome [15], while the in-
flammatory lesions [16], i.e. the proportion of crescents,
predicted the response to immunosuppressive therapy
and the proportion of sclerotic glomeruli was related to
a worse renal prognosis [17, 18]. More recently, a panel
of international renal pathologists proposed and validated
the first classification for ANCA vasculitis: patients in the
sclerotic class (≥50 % sclerotic glomeruli) had the worst
renal prognosis, followed in order by those in the mixed
(<50 % normal, <50 % crescents, <50 % sclerotic), cres-
centic (≥50 % crescents) and focal (≤50 % crescents) class
[19]. The prognostic utility of this classification was con-
firmed in some but not all subsequent studies [20–23].
We aimed to evaluate ANCA phenotypes, kidney and
patient outcome in a cohort of Central-East European
patients with severe crescentic glomerulonephritis ad-
mitted in a tertiary Nephrology center in relation with
ANCA specificity and histopathological classification.
Methods
Patients
This is a retrospective cohort study on all adult patients con-
secutively diagnosed by kidney biopsy with pauci-immune
crescentic glomerulonephritis and followed in a single
Nephrology center serving a population of about 4.85 mil-
lion. From January 2000 till January 2014, pauci-immune
crescentic glomerulonephritis were diagnosed in 104 pa-
tients. Thirteen patients were excluded because they were
ANCA negative, 4 because of incomplete data and 12
were lost to follow-up.
The final cohort comprised 75 patients with ANCA
positive pauci-immune crescentic glomerulonephritis
who were followed over a median period of 3.2 [0.1;
5.5] years.
All subjects signed an informed consent form authorising
us to use their demographic and medical data in this study.
The study was performed in accordance with Helsinky
Declaration and it was approved by the local Ethics
Committee of the “Dr. Carol Davila” Teaching Hospital
of Nephrology.
Diagnosis and follow-up
The criteria for pauci-immune crescentic glomeruloneph-
ritis diagnosis were crescents (cellular and/or fibrous) in at
least 50 % of examined glomeruli by light microscopy and
a direct immunofluorescence assay of 0 to 1+ on a scale
from 0 to 4+ [24]. For this study, all the biopsies were
reviewed by our pathologist and they were classified in
four classes as proposed by Berden et al.: crescentic
(≥50 % glomeruli with cellular crescents), focal (≥50 %
normal glomeruli), sclerotic (≥50 % sclerotic glomeruli) or
mixed (<50 % normal glomeruli, <50 % glomeruli with cel-
lular crescents, <50 % sclerotic glomeruli ) [19].
ANCAs were assessed by capture PR3-ANCA and MPO –
ANCA ELISA (Euroimmun™, Lübeck, Germany) or by
indirect immunofluorescence (monoclonal mouse anti-
human myeloperoxidase antibodies Dako™, Glostrup,
Denmark).
Markers of kidney damage were proteinuria measured
in 24 h urine collection, hematuria (macroscopic and
microscopic, red blood cells casts), serum creatinine and
the histopathologic classes.
Hemorrhagic alveolitis was diagnosed based on chest ra-
diographs and acute anemia without evidence of another
external bleeding, and was classified as severe when oxy-
gen partial pressure in arterial blood decreased under
60 mmHg. Severe anemia was defined as hemoglobin level
less than 7 g/dL.
Inflammation was assessed using erythrocyte sedimenta-
tion rate (ESR), serum fibrinogen, serum albumin, platelet
count and white blood cells count.
The measurements were performed by standard la-
boratory methods on an Olympus AU 400 chemistry
auto-analyzer, and a MINDRAY BC 3000 hematology
auto-analyzer.
The severity of vasculitis was evaluated using Birmingham
Vasculitis Activity Score ver. 3 (BVAS) [25].
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The follow-up protocol included monthly visits with
clinical (BVAS) and laboratory evaluation, until remis-
sion and every 3 months thereafter.
Response to therapy was defined as disappearance of
hematuria, stable or improving serum creatinine and no
signs of activity in other organs [26].









Gender (% Male) 48 78 39 0.004
Age >65 years (%) 35 11 42 0.02
Age (years) 60 [53; 68] 58.0 [43; 62] 63 [55; 69] 0.01
Cold season at diagnosis 60 % 65 % 62 % 0.81
Time to diagnosis (mo) 2.0 [1.0; 5.6] 1.5 [1.0; 3.0] 2.0 [1.0; 6.0] 0.12
Vasculitis symptoms
Constitutional (%) 84 94 81 0.17
Skin (%) 9 17 7 0.22
Ocular (%) 3 11 0 0.01
Upper respiratory (%) 8 22 4 0.01
Lung (%) 48 50 47 0.85
Severe lung hemorrhage 31 % 39 % 28 % 0.39
Kidney (%) 100 100 100 1.00
Digestive (%) 4 0 5 0.32
CNS (%) 4 0 5 0.32
Organs affected (No) 2 [1; 2] 2 [1; 3] 2 [1; 2] 0.08
BVAS 17 [15; 21] 21 [15; 22] 17 [15; 20] 0.05
Inflammation
Hemoglobin (g/dL) 8.5 [7.5; 9.8] 7.7 [5.7; 9.5] 9.0 [7.8; 9.8] 0.04
Severe anemia (%) 35 56 28 0.03
WBC (per mm3) 9750 [7800; 14400] 10700 [7800; 15075] 9650 [7683; 13900] 0.64
ESR (mm/1 h) 97 [64; 120] 100 [80; 140] 94 [63; 120] 0.18
Fibrinogen (mg/dL) 680 [568; 800] 714 [608; 806] 670 [547; 800] 0.48
Serum albumin (mg/dL) 3.6 [3.10; 4.0] 3.3 [2.9; 3.7] 3.7 [3.1; 4.0] 0.15
Kidney disease
Histopathologic class
Crescentic (%) 52 67 47 0.52
Focal (%) 5 6 5
Mixed (%) 32 22 35
Sclerotic (%) 11 6 12
Creatinine (mg/dL) 5.0 [3.4; 7.9] 7.2 [4.2; 10.0] 4.8 [3.1; 7.2] 0.04
Proteinuria (g/day) 0.8 [0.5; 2.2] 1.0 [0.4; 1.4] 0.8 [0.5; 2.3] 0.73
Hematuria (per mm3) 260 [190; 800] 535 [288; 1200] 230 [183; 623] 0.005
Macroscopic hematuria 44 % 78 % 33 % 0.001
RBC casts (%) 37 72 28 0.02
Dialysis at presentation 27 % 50 % 19 % 0.01
Values are median [quartile 1; quartile 3] if not otherwise specified
mo months, CNS Central nervous system, No number, BVAS Birmingham Vasculitis Activity Score, WBC white blood cells, ESR erythrocyte sedimentation rate,
RBC red blood cells
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Dialysis therapy was considered temporary when needed
for less than 3 months.
Study end-points were response to therapy, end stage
renal disease (ESRD) and death.
Therapy
Induction therapy was done with steroids (3 daily intra-
venous pulses with methylprednisolone 0.5–1 g then pred-
nisone 0.5 mg/kg daily, gradually tapered after one month)
associated with cyclophosphamide 0.5 g/m2, two pulses in
the first month, then one pulse monthly for the next five
months in the majority of patients (the mean cumulative
cyclophosphamide dose was 4.6 g). Maintenance therapy
consisted in prednisone (10 mg daily in the first year and
7.5 mg daily afterwards) and azathioprine 1.5–2 mg/kg per
day for at least 2 years. Plasmapheresis was only occasion-
ally performed (5 patients), usually in case of severe
hemorrhagic alveolitis, because this therapy is not reim-
bursed by the health insurance authority.
Statistical analysis
Categorical variables are presented as percentages and
comparison tests were performed using Pearson χ2 test.
Continuous variables are displayed as mean with 95 %
confidence interval (95 % CI) or median and quartiles
[1; 3], according to their distribution. Comparisons were
done with ANOVA, Mann-Whitney and Kruskal-Wallis
tests, as appropriate.
Survival analyses were conducted with the Kaplan-Meier
method and Mantel-Cox log-rank test for comparisons.
Models of binomial or multinomial logistic regression were
built to estimate differences between groups at presenta-
tion. Multivariate Cox proportional hazard ratios (PHR)
models were used to evaluate parameters associated with
various outcomes.
A p ≤ 0.05 was considered statistically significant.
Statistical analyses were performed with SPSS (SPSS
Inc., Chicago, IL) and Analyse-it™ (Analyse-it Software,
Ltd., Leeds, UK) packages.
Results
Patients’ characteristics at presentation
Table 1 shows the baseline characteristics of patients.
The clinical condition at presentation was severe (me-
dian BVAS 17). All patients had severe kidney disease
(median creatinine 5 mg/dL, 27 % needed dialysis). The
lung was the second most affected organ; 31 % of patients
had severe hemorrhagic alveolitis. The odds of hemorrhagic
alveolitis in patients needing dialysis at presentation were 4
(95 % CI 1–13; p = 0.006) times higher than in those who
did not.
Most patients (76 %) were MPO-ANCA positive. PR3-
ANCA patients were younger, in higher proportion
male, had higher BVAS, resulting from more frequent
upper respiratory tract and eye symptoms and more
severe kidney damage (Table 1, Fig. 1).
Most of the patients (52 %) were in the crescentic his-
topathologic class. PR3-ANCA and MPO-ANCA speci-
ficities had a similar distribution in the histopathologic
classes (Table 1).
When evaluated by logistic regression, in patients with
creatinine ≥5 mg/dL, PR3-ANCA was associated with
male gender and dialysis at presentation (Table 2).
Response to therapy
Forty-five patients (60 %) responded to the induction ther-
apy in 4 [2; 6] months. Neither the histopathologic class
nor the ANCA specificity influenced the rate of response.
In multivariate Cox regression analysis, although older
patients and those with higher platelets number responded
better, the need for dialysis at presentation was the most
powerful predictor of response: the hazard ratio of response
was two and a half times higher in patients not needing dia-
lysis at presentation (Table 3).
Kidney outcome
Of the 51 patients alive at the end of the observation





































Fig. 1 Prevalence of organs affected according to ANCA serology. Legend: numbers represent percent from 75 patients which presented with
the mentioned type of vasculitis manifestation; percents in red means statistically significant difference (p < 0.05). CNS Central nervous system
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As compared to dialysis dependent-patients, those
dialysis-free were older females and had less severe kidney
disease at presentation (lower creatinine levels, lower
proteinuria and hematuria). The kidney survival was not
influenced by the vasculitis severity, ANCA serology or
the histopathological class (Table 4).
The unadjusted probability of kidney survival 1 and
5 years was 93 % and 64 %. The median ESRD-free
survival time was longer in responders to induction
therapy and in those who did not need dialysis at
presentation (Fig. 2). In a Cox PHR model, the re-
sponse to induction therapy and dialysis at presenta-
tion were retained as independent predictors of
kidney survival. The responders had thirty four times
more chances to avoid ESRD (HR = 33.88, 95 % CI
9.13–125.55, p < 0.001), while those not needing dialy-
sis at presentation had a 84 % lower risk of kidney
death (HR = 0.16, 95 % CI 0.05–0.48, p = 0.001).
Patient outcome
Fifty one (68 %) patients survived. The main cause
of death was pulmonary hemorrhage (n = 9; 38 % of
deaths).
Surviving patients had less severe vasculitis (lower
BVAS), less severe kidney disease (lower creatinine and
hematuria, and fewer needed dialysis at presentation)
and higher serum albumin levels. They responded in
higher proportion to induction therapy. ANCA specifi-
city and the histopathological class did not influence the
patient outcome (Table 5).
The median survival was 7.2 years, and the cumula-
tive survival 1 and 5 years was 88 % and 67 %. In a Cox
PHR model, the independent predictors of death were a
higher BVAS - for each increase in BVAS with three
units, the risk of death was six times higher (HR = 5.88,
95 % CI 1.03–33.58, p = 0.05) - and the response to
induction therapy - non-responders had five times
less chances of survival (HR = 0.20, 95%CI 0.07–0.53,
p = 0.0001) (Fig. 3).
Discussion
This study reports the outcome in a cohort of Central
East European patients with pauci-immune crescentic
glomerulonephritis, where MPO-ANCA specificity was
predominant, and the kidney damage severe and associ-
ated with lung hemorrhage. The patient and kidney out-
comes were mainly influenced by the severity of kidney
Table 4 Patients’ characteristics according to kidney outcome
Parameter End stage renal disease P value
No Yes
Patients number 38 13
General
Gender (% Male) 47 69 0.01
Age (years) 63 [53; 69] 51 [35; 57] 0.01
Vasculitis
PR3-ANCA (%) 64 36 0.37
MPO-ANCA (%) 78 22
Severe lung hemorrhage (%) 24 39 0.30
BVAS 15 [13; 21] 16 [15; 21] 0.63
Response to induction
therapy
97 % 15 % <0.0001
Inflammation
Hemoglobin (g/dL) 9.0 [7.8; 10.0] 8.0 [6.0; 9.0] 0.07





ESR (mm/1 h) 99 [65; 115] 110 [82; 140] 0.28
Fibrinogen (mg/dL) 717 [578; 800] 720 [612; 820] 0.97
Albumin (g/dL) 3.8 [3.2; 4.0] 3.5 [3.1; 3.9] 0.25
Kidney
Histopathologic class
Crescentic (%) 46 67 0.28
Focal (%) 7 0
Mixed (%) 33 29
Sclerotic (%) 13 5
Creatinine (mg/dL) 4.0 [2.9; 5.8] 9.0 [4.5; 12.0] 0.006
Proteinuria (g/day) 0.6 [0.4; 1.5] 2.3 [1.2; 3.0] 0.007
Hematuria (per mm3) 210 [150; 290] 460 [230; 980] 0.003
Dialysis at presentation (%) 8 62 <0.0001
Values are median [quartile 1; quartile 3] if not otherwise specified
PR3-ANCA patients positive for anti-proteinase 3 antibodies, MPO-ANCA patients
positive for anti-myeloperoxidase antibodies, BVAS Birmingham Vasculitis Activity
Score, WBC white blood cells, ESR erythrocyte sedimentation rate
Table 3 Predictors of the response to therapy; Multivariate Cox
proportional hazards regression analysis
Variables B S.E. Exp. (B) 95 % CI Sig.*
Age >65 years (No) −0.87 0.35 0.42 0.21 0.84 0.01
Ln (Platelets) 1.36 0.51 3.91 1.44 10.59 0.01
Albumin 0.78 0.40 2.18 0.99 4.77 0.05
Dialysis at presentation (No) 0.91 0.52 2.47 0.89 6.87 <0.0001
B coefficient b, S.E. standard error of coefficient b, Exp. (B) hazard ratio,
CI confidence interval, Ln logarithm
*p ≤ 0.01 statistically significant
Table 2 Differences in clinical presentation according to
ANCA serology
Variables in equationa B S.E. Exp(B) 95 % CI Sig.b
Gender (Male) 2.92 1.20 18.61 1.76 196.91 0.02
Dialysis at presentation (Yes) 2.10 0.92 8.16 1.34 49.56 0.02
Constant −0.93 0.68 0.40 0.17
aSelection variable: Creatinine ≥5 mg/dL
bCox & Snell R square 0.46; Hosmer & Lemeshow Goodness of fit p = 0.99
Reference category is MPO-ANCA
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damage at presentation and by the response to induction
therapy, but not by ANCA specificity, suggesting that the
severity of organ lesions could overcome the ANCA-
related phenotypic differences. Moreover, the severity of
kidney lesions influenced the patients’ distribution in the
histopathological classes, which probably limited its prog-
nostic utility. In our cohort, median age was 60 years and
gender distribution was balanced, as was reported in other
series [1–3, 11, 18, 27–30]. The majority of cases were di-
agnosed in cold seasons, which suggest that upper respira-
tory tract infections were triggers of autoimmunity [31,
32]. The median lag between first symptoms and diagnosis
was 2 months, highlighting the difficulty to recognize
these protean diseases, in line with other reports [1, 29].
The main feature of this cohort was severe kidney dis-
ease (median creatinine 5 mg/dL; 27 % of patients
needed dialysis at presentation). As in other series of
vasculitis with severe kidney involvement [8, 30], the
clinical condition was poor at presentation; 25 % of pa-
tients had BVAS >21. The lung was the second most
affected organ; 31 % of patients had severe hemorrhagic
alveolitis. Moreover, there was a strong correlation
between the severity of kidney and lung disease. The
odds of severe hemorrhagic alveolitis were four times
higher in patients needing dialysis at presentation.
Although a high frequency of lung involvement in patients
with severe kidney disease was observed in other series
[7], the clinical significance of this association had not yet
been underlined. It could be explained by the severity of
vasculitis involving both organs, amplified by the conse-
quences of severe uremia on capillary permeability favor-
ing lung bleeding. MPO specificity was 3 times more
frequent than PR3 specificity, lower than reported in the
United Kingdom and Norway, but closer to reports
from Spain, which supports a South to North gradient
of MPO specificity distribution across Europe [33]. In
this cohort with MPO-ANCA dominance and severe kid-
ney disease, male gender and the need for dialysis at pres-
entation were significantly associated with PR3-ANCA
when serum creatinine was above 5 mg/dL. This is in con-
trast with other studies which reported similar [1, 4, 34]
or worse [9] kidney disease at presentation in MPO-
ANCA, not in PR3-ANCA. This discrepancy could be ex-
plained by the faster pre-admission deterioration of kidney
function in PR3-ANCA [4] or by a combination of late re-
ferral with a selection bias, as patients were specifically re-
ferred because of severe kidney damage. On the other
hand, the severity of kidney disease at presentation could
have offset the phenotypic differences between MPO and
PR3. However, our data suggest that in regions where
MPO-ANCA incidence is high, the possibility of severe
kidney disease in PR3-ANCA patients in a nephrology set-
ting should be kept in mind.
The rate of complete remission was 60 %, lower than
that reported in controlled trials (75–85 %) [35–37],
where responsiveness was related mainly to the thera-
peutic protocols, but closer to that reported in observa-
tional studies (50–75 %) [27, 30, 38, 39]. Possible
explanations of the low rate of response are the severe
clinical presentation and the infrequent use of plasma-
pheresis. In line with other cohorts of patients with
severe kidney disease, in our patients the kidney failure
described by the need for dialysis at presentation was an
independent predictor of resistance to therapy while the
ANCA pattern was not [8, 27, 38]. Thus, in a nephrology
setting, the severity of kidney disease seems to overcome
the prognostic significance of other factors. Interestingly, a
higher platelets number was related to a positive response,
as originally observed and interpreted by Westman [2] as
reflecting a more severe immunological injury, not
Dialysis at presentation 
No 
Yes 
Response to therapy 
No 
Yes 
Fig. 2 Adjusted cumulative kidney survival according to the response to induction therapy (left) and to the need of dialysis at presentation (right).
Legend: The median ESRD-free survival time was longer in responders to induction therapy [4.5 (4.1–4.9) vs. 1.0 (0.3–1.6) years; p < 0.0001] and in those
who did not need dialysis at presentation [4.1 (3.6–4.7) vs. 0.9 (0.3–1.6) years; p < 0.0001]. ESRD End stage renal disease
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necessarily accompanied by more inflammation. This is
also supported by our data showing higher albumin levels
in responders and no difference in ESR or fibrinogen
levels. Contrary to other series, older age was an indicator
of a positive response. Possible explanations are a lower
intensity of immune injury in elderly and increased disease
awareness in elderly driving them to seek medical assist-
ance in our particular population.
In spite of severe kidney disease at presentation, 51 %
of our patients were alive and dialysis free at the end of
the observation period, which is similar to reports from
studies enrolling vasculitis patients with severe kidney
dysfunction (56–64 %) [29, 40]. Moreover, the probabil-
ity of kidney survival 5 years was comparable in our
cohort to that reported in patients with similar kidney
dysfunction at presentation [2, 29]. Unlike other studies
where markers of kidney damage (serum creatinine [1,
2]), urinary IgM [41] or ANCA pattern [2, 28] predicted
ESRD, in our series the resistance to induction therapy
and the need of dialysis at presentation were the
independent predictors of kidney death. On the other
hand, 27 % of patients needing dialysis at presentation
regained enough renal function to become dialysis-free
at the end of the observation period. Accordingly, ag-
gressive induction therapy is justified even in case of se-
vere kidney failure. Simultaneously, it is to note that the
severity of kidney status at presentation overwhelmed
the severity of inflammation, the other organs lesions as
well as ANCA specificity and the histopathological class
as predictors of kidney death.
While kidney survival was associated with the initial
organ damage, patient’s survival depended on vasculitis
activity at presentation as reflected by BVAS. Several
studies reported associations between BVAS and long
term outcome [3, 42]. We observed a 6 times increase in
risk of death for each three units rise in BVAS, which is
in line with data reported in the largest multinational
cohort of patients with ANCA-associated vasculitis
where a small but significant effect of BVAS on survival
was also found [3]. Thus, our data support the prognos-
tic utility of BVAS and suggest a link between the initial
organs damage and the long term prognosis, even when
the clinical picture is dominated by the severity of
kidney disease.
The other independent predictor of death was the
response to induction therapy; the responders had five
times more chances of survival than non-responders. As
induction therapy was conducted according to current
guidelines, including dose adjustment to renal function
and age, this further underlines the limits of the existing
therapeutic regimens.
Other studies reported differences in long term sur-
vival related to ANCA specificities [27, 28] while in our
data neither kidney nor patient survival was related to
ANCA serology. Nevertheless, in the previously men-
tioned EUVAS cohort, no ANCA-related dissimilarities
in outcome were found and Flossmann et al. commen-
ted that previously reported differences in outcome
could have been artifactual, caused by case-mix and
underpowered adjustment for age and kidney damage
[3]. Alternatively, when the consequences of vasculitis
are severe - i.e. extensive kidney or other organs
damage - they can conceal the initiating mechanism
(ANCA specificity).
A histopathological classification of ANCA-associated
glomerulonephritis was recently proposed by Berden
et al. [19], aiming to improve prognosis of renal outcome
and, eventually, to guide therapy. In our cohort, the pro-
portions were similar in the case of the crescentic and
Table 5 Patients’ characteristics according to outcome
Parameter Patients’ death P value
No Yes
Patients number 51 24
General
Gender (% Male) 53 38 0.21
Age (years) 60 [50; 68] 63 [60; 68] 0.14
Vasculitis
MPO-ANCA (%) 65 35 0.31
PR3-ANCA (%) 78 22
Severe lung hemorrhage (%) 29 39 0.39
BVAS 15 [14; 21] 20 [17; 21] 0.01
Response to induction
therapy
76 % 25 % <0.0001
Inflammation






ESR 100 [78; 120] 80 [61; 120] 0.20
Fibrinogen 720 [578; 820] 645 [525; 750] 0.15
Serum albumin 3.7 [3.2; 4.0] 3.2 [2.8; 3.6] 0.008
Kidney
Histopathologic class
Crescentic (%) 49 58 0.5
Focal (%) 4 8
Mixed (%) 33 29
Sclerotic (%) 14 4
Serum creatinine (mg/dL) 4.7 [3.0; 7.4] 6.9 [4.1; 8.0] 0.06
Proteinuria 0.9 [0.5; 2.2] 0.8 [0.6; 2.2] 1.00
Hematuria 230 [180; 670] 365 [240; 1600] 0.008
Dialysis at presentation (%) 22 38 0.15
Values are median [quartile 1; quartile 3] if not otherwise specified
PR3-ANCA patients positive for anti-proteinase 3 antibodies, MPO-ANCA patients
positive for anti-myeloperoxidase antibodies, BVAS Birmingham Vasculitis Activity
Score, WBC white blood cells, ESR erythrocite sedimentation rate
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sclerotic classes (52 vs 55 % and 11 vs 13 %), higher in
the case of the mixed class (32 vs 16 %) and lower in the
case of the focal class (5 vs 16 %) than reported by
Berden et al. [19]. These differences could be due to a
selection bias, as our patients were selected by the
severity of kidney damage (which resulted in a lower
frequency of focal class and a higher one in the mixed
class), or to a limited reproducibility of the classification,
as suggested by Ford et al. [20]. In our data, the histo-
pathological classes were related neither to kidney func-
tion at presentation nor to kidney or patient outcome.
However, our study had a low number of participants,
which imposes caution in interpretation. Nevertheless,
the validity of this classification was evaluated only in
few studies so far and further research is clearly
needed [20–23].
There are some limits of our study. The number of
participants was low and the period of observation
rather short, both limiting the statistical power. The
single center design could be a limit for extrapolation of
the results to other population, but data on Central East
European population are scarce and on the other hand,
this design increases the accuracy of data collection.
ANCA were assessed by indirect immunofluorescence
and/or by ELISA, and discrepancies between results
obtained by these methods were described.
Conclusions
In ANCA positive pauci-immune crescentic glomerulo-
nephritis, the kidney and patient outcomes are related to
the severity of kidney damage at presentation and to the
response to therapy, but not to ANCA specificity or to
the histopathological class. Thus, “the blast” - the acute
injury inducing severe organ damage - results in a peculiar
distribution in histopathological classes, reduced respon-
siveness to therapy and poorer outcome, and could hide
the prognostic influence of both “the trigger” - i.e. ANCA
specificity - and of the histopathology lesions.
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